Table 5.
Total change | oCEE | tE2 | Placebo | Overall | Pairwise P-value |
|
---|---|---|---|---|---|---|
(n = 23) | (n = 24) | (n = 31) | P-value | oCEE / Placebo | tE2 / Placebo | |
WMH (cm3) | 0.54 (0.60) | 0.52 (0.77) | 0.18 (0.28) | 0.06* | 0.12* | 0.11* |
FSH (IU/L) | −23 (21) | −33 (38) | 7 (26) | <0.001 | 0.001 | <0.001 |
LH (IU/L) | −6 (14) | −13 (16) | −3 (10) | 0.04 | 0.81 | 0.04 |
E1 (pg/mL) | 65 (60) | 19 (22) | −4 (22) | <0.001 | <0.001 | 0.07 |
E2 (pg/mL) | 5 (15) | 29 (39) | −10 (34) | <0.001 | 0.22 | <0.001 |
Data are mean (SD)
Abbreviations; oCEE = oral conjugated equine estrogens, tE2 = transdermal estradiol, FSH = follicle stimulating hormone, LH = luteinizing hormone, E1 = estrone, E2 = estradiol, TIV = total intracranial volume, WMH = white matter hyperintensity
models adjusted for log-transformed TIV